Research Models
Selected Results
1 Models
| Name | Other Names | Strain Name | Genetic Background | Gene | Mutation | Modification Info | Modification | Disease | Neuropathology | Behavior/Cognition | Other Phenotype | Availability | Primary Paper | Visualization | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mouse Models (1)
|
|||||||||||||||
| <p>-</p>, <p>APOE2 Humanized Knock-in</p> | B6.129P2-Apoetm1(APOE*2)Mae N9 | 129 x C57BL/6; back-crossed to C57BL/6 | APOE | APOE R176C (ApoE2) | Targeted gene replacement of the endogenous murine APOE gene with the human APOE2 allele. Targeting construct included exons 2-4 of APOE2. | APOE: Knock-In | Alzheimer's Disease, Multiple Conditions | None reported. White-matter integrity, as assessed by fractional anisotropy, was reported to be higher in the hippocampus and caudate putamen of year-old female APOE2 mice, compared with APOE3 females; these genotype differences were not seen in males. | Findings are mixed, with some studies reporting that APOE genotype—in some cases, interacting with sex or age—affects performance in behavioral assays. | Characteristics of type III hyperlipoproteinemia. Plasma cholesterol and triglyceride levels 2-3x higher than APOE3 mice. Impaired clearance of very-low-density lipoprotein (VLDL) particles. Atherosclerotic plaques. Compared with APOE3 mice, APOE2 mice exhibited higher levels of glucose uptake in the cortex and hippocampus and up-regulation of genes involved in glucose utilization. | Taconic: Stock# 1547-F and 1547-M | Sullivan et al., 1998 | No | ||